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6.	 PKU	 women	 during	 pregnancy	 need	 a	
strict	 control	 of	 their	 blood	 Phe	 level	
in	 order	 to	 prevent	 severe	 embryo-
foetopathy	 (maternal	 PKU);	 there	 are	
not	 enough	 data	 on	 the	 use	 of	 BH4	 in	
pregnancy	 in	 responsive	 patients	 and	
its	 use	 is	 therefore	 not	 recommended.	
However,	 in	 patients	 with	 major	 prob-










8.	 The	 SGIEM	 recommends	 that	 pharmaco-
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phenylketonuria:	 a	 phase	 III,	 randomized,	 double-










BH4	 is	 the	 natural	 cofactor	 of	 the	 enzyme	









metabolic	 centers,	 as	 a	 limited	 number	 of	
PKU	 patients	 have	 been	 treated	 with	 BH4	
since	2003.	Due	to	the	recent	introduction	of	
Sapropterin	(Kuvan®)	on	the	Swiss	market	by	
Merk-Serono,	 BH4	 therapy	 has	 become	 far	
more	expensive	than	dietary	treatment.	In	or-
der	to	provide	a	reasonable	and	homogenous	
approach	 to	 the	 treatment	 of	 PKU	 patients	
with	 BH4	 in	 Switzerland,	 the	 Swiss	 Group	
for	Inborn	Errors	of	Metabolism	(SGIEM)	has	
reached	consensus	on	criteria	for	treatment	








only	 in	 PKU	 patients	 requiring	 dietary	
treatment	(blood	Phe	level	>	400	µmol/L);	





2.	 BH4	 should	 be	 used	 in	 PKU	 patients	
without	 age	 restriction	 (off-label	 use	
under	 4	 years	 of	 age).	 Assessment	 of	
BH4	 responsiveness	 is	 recommended	
either	at	diagnosis	(newborn	screening)	
or	 once	 individual	 Phe	 tolerance	 has	
been	defined,	which	may	be	best		before	
weaning	(4–5	months	of	age).	
3.	 Only	 fully	 responsive	 PKU	 patients	
should	 be	 considered	 for	 treatment.	
Fully	 responsive	patients	should	 reach	
a	Phe	intake	corresponding	to	the	mini-
mum	 safe	 protein	 intake	 for	 age	 (ac-
cording	 to	 DACH	 Reference	 values)	
under	BH4.	Partially	responsive	patients	
exist,	who	increase	their	Phe	tolerance	






4.	 Assessment	 of	 BH4	 responsiveness	
should	be	done	in	the	following	way:
a.	 Therapeutic	 trial	 with	 BH4	 10	 mg/
kg/day	(1x/day)	for	4	weeks,	regard-
less	of	baseline	blood	Phe	levels.	
b.	 Blood	 Phe	 controls	 2x/week;	 daily	
dietary	 protocol	 for	 Phe	 intake	 cal-
culation.
c.	 Progressive	 increase	 of	 Phe	 intake	
up	 to	 a	 level	 corresponding	 to	 the	
minimum	safe	protein	intake	for	age	






d.	 Responsive	 patients	 should	 keep	
blood	 Phe	 levels	 below	 the	 recom-
mended	 thresholds	 for	 age	 while	
receiving	a	diet	corresponding	to	the	
minimum	safe	protein	intake	for	age	
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